Cenerimod clinical trials
Also written ACT-334441.
How each study uses cenerimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cenerimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Viatris Innovation GmbH (13) · Viatris Pharmaceuticals Co., Ltd. (1)
Often tested with
Tested in the same studies.
Contraceptives, Oral, Combined (1) · Moxifloxacin (1) · Atenolol (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test cenerimod, phase 3 first.
- Dec 2026A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusPhase 3 · Viatris Innovation GmbH
- Mar 2027A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusPhase 3 · Viatris Innovation GmbH
- Oct 2027A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)Phase 2 · Viatris Pharmaceuticals Co., Ltd.
Studies
Open first, then newest update. How each study uses cenerimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusEnrolling by invitationPhase 3Viatris Innovation GmbHNCT06475742Written as Cenerimod
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentRecruitingPhase 3Viatris Innovation GmbHNCT07201129Written as Cenerimod
- A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusActive, not recruitingPhase 3Viatris Innovation GmbHNCT05672576Written as Cenerimod
- A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusActive, not recruitingPhase 3Viatris Innovation GmbHNCT05648500Written as Cenerimod
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus ErythematosusCompletedPhase 1/2Viatris Innovation GmbHNCT02472795Written as Cenerimod
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusCompletedPhase 2Viatris Innovation GmbHNCT03742037Written as Cenerimod 0.5 mg
- A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)Active, not recruitingPhase 2Viatris Pharmaceuticals Co., Ltd.NCT07266090Written as cenerimod 4 mg
- A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male ParticipantsCompletedPhase 1Viatris Innovation GmbHNCT07301723Written as Cenerimod (oral)
- Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian SubjectsCompletedPhase 1Viatris Innovation GmbHNCT04052360Written as Cenerimod
- A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of CenerimodCompletedPhase 1Viatris Innovation GmbHNCT04819464Written as Cenerimod
- A Study to Evaluate Cenerimod in Healthy Male SubjectsCompletedPhase 1Viatris Innovation GmbHNCT02914223Written as Cenerimod
- To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.CompletedPhase 1Viatris Innovation GmbHNCT04255277Written as Cenerimod 0.5 mg
- The Effect of Severe Kidney Impairment on Cenerimod PharmacokineticsCompletedPhase 1Viatris Innovation GmbHNCT05004311Written as Cenerimod
- Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441TerminatedPhase 1Viatris Innovation GmbHNCT02479204Written as ACT-334441 2 mg
Codes
What other systems call cenerimod · ClinicalTrials.gg INT001390
- MeSH (NLM) C000709569cenerimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Y333RS1786CENERIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q27294201cenerimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169837CenerimodOne source FDA
- DrugBank DB12705One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709569 | cenerimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Y333RS1786 | CENERIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27294201 | cenerimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169837 | Cenerimod | One source FDA |
| DrugBank | DB12705 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.